GeoVax Labs is a clinical-stage biotechnology company focused on developing human vaccines that fight infectious diseases using its novel vaccine platform. The company centers its attention on developing vaccines against Ebola and Marburg viruses, and human immunodeficiency virus (HIV). Its vaccines under development include GOVX-B11 and GOVX-B21 vaccines that are in phase 2a clinical trials to treat clade B subtype of HIV virus; and in preclinical research to treat clade C subtype of HIV virus. Founded in 2001, the company is based in Smyrna, Georgia.  For more information, visit the company’s website at www.geovax.com